TY - JOUR
T1 - A validated prognostic classifier for V600E BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.
AU - Loupakis, Fotios
AU - Intini, Rossana
AU - Cremolini, Chiara
AU - Orlandi, Armando
AU - Sartore-Bianchi, Andrea
AU - Pietrantonio, Filippo
AU - Pella, Nicoletta
AU - Spallanzani, Andrea
AU - Dell'Aquila, Emanuela
AU - Scartozzi, Mario
AU - De Luca, Emmanuele
AU - Rimassa, Lorenza
AU - Formica, Vincenzo
AU - Leone, Francesco
AU - Calvetti, Lorenzo
AU - Aprile, Giuseppe
AU - Antonuzzo, Lorenzo
AU - Urbano, Federica
AU - Prenen, Hans
AU - Negri, Francesca
AU - Di Donato, Samantha
AU - Buonandi, Pasquale
AU - Tomasello, Gianluca
AU - Avallone, Antonio
AU - Zustovich, Fable
AU - Moretto, Roberto
AU - Antoniotti, Carlotta
AU - Salvatore, Lisa
AU - Calegari, Maria Alessandra
AU - Siena, Salvatore
AU - Morano, Federica
AU - Ongaro, Elena
AU - Cascinu, Stefano
AU - Santini, Daniele
AU - Ziranu, Pina
AU - Schirripa, Marta
AU - Buggin, Federica
AU - Prete, Alessandra Anna
AU - Depetris, Ilaria
AU - Biason, Paola
AU - Lonardi, Sara
AU - Zagonel, Vittorina
AU - Fassan, Matteo
AU - Di Maio, Massimo
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Despite the well-known negative prognostic value of the BRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. Two large retrospective series of BRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. A total of 395 BRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p
AB - Despite the well-known negative prognostic value of the BRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. Two large retrospective series of BRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. A total of 395 BRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p
KW - (V600E)BRAF
KW - Colorectal cancer
KW - Metastases
KW - Prognostic markers
KW - Scoring system
U2 - 10.1016/j.ejca.2019.06.008
DO - 10.1016/j.ejca.2019.06.008
M3 - Articolo
VL - 118
SP - 121
EP - 130
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -